Pelthos Therapeutics Inc.
PTHSAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 26, 2026 | Industrial Alliance Securities | James Molloy | $30.00(+76%) | $17.00 | TheFly |
| Oct 12, 2026 | Lake Street | $40.00(+98%) | $20.17 | TheFly | |
| Aug 14, 2026 | Oppenheimer | Jeff Jones | $64.00(+131%) | $27.75 | TheFly |
| Aug 13, 2026 | Industrial Alliance Securities | $45.00(+55%) | $29.07 | TheFly | |
| May 15, 2026 | Oppenheimer | Jeff Jones | $66.00(+138%) | $27.69 | TheFly |
| Feb 26, 2026 | Roth Capital | $55.00(+139%) | $23.00 | TheFly | |
| Jan 26, 2026 | Oppenheimer | $60.00(+142%) | $24.75 | TheFly | |
| Dec 3, 2025 | Lake Street | $50.00(+83%) | $27.38 | TheFly | |
| Dec 3, 2025 | H.C. Wainwright | $60.00(+139%) | $25.14 | TheFly | |
| Nov 25, 2025 | Roth Capital | $57.00(+107%) | $27.53 | TheFly | |
| Sep 2, 2025 | UBS | $50.00(+123%) | $22.46 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Lake Street | maintain | Buy | Oct 12, 2026 |
| Oppenheimer | maintain | Outperform | Aug 14, 2026 |
| Oppenheimer | maintain | Outperform | May 15, 2026 |
| Oppenheimer | maintain | Outperform | Mar 20, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 19, 2026 |
| Roth Capital | maintain | Buy | Feb 26, 2026 |
| Oppenheimer | maintain | Outperform | Jan 26, 2026 |
| Oppenheimer | maintain | Outperform | Nov 14, 2025 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-3.08| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-6.62 | $-2.82 | $15.6M | $15.2M |
| May 14, 2026 | $-3.09 | $-3.45 | $10.9M | $10.4M |
| Mar 19, 2026 | $-6.87 | $-3.95 | $9.4M | $9.1M |
| Nov 13, 2025 | $-5.30 | $-0.67 | $7.4M | $4.4M |
| Aug 13, 2025 | $-5.38 | $-5.82 | — | $4.4M |
| May 13, 2025 | $-3.21 | $-2.90 | $150.0K | — |
| Mar 27, 2025 | $-3.23 | — | — | — |
| Nov 13, 2024 | $-2.90 | $-2.30 | — | — |
News
DURHAM, N.C., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it will report third quarter 2026 financial results on Thursday, November 12, 2026.
Strategic Combination Brings Highly Innovative Late-Stage D-Fi Franchise Targeting Rare Diseases, with Orphan Drug-Designated Lead Indication in Dystrophic Epidermolysis Bullosa (DEB)
Board appointments align with successful transition to late-stage clinical Company developing pemvidutide as a differentiated liver franchise with multiple potential indications As part of this transition, John M. Gill, Mitchel Sayare, Ph.D.
Company secures new formulary coverage with a major Pharmacy Benefit Manager, reaching an additional 24 million covered lives Pelthos gains enhanced commercial coverage through a regional commercial health plan representing approximately 3 million covered lives Formulary coverage for ZELSUVMI increases to 127 million commercially covered lives DURHAM, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing …
Pelthos Therapeutics NYSEAMERICAN: PTHS reported second-quarter revenue growth as prescriptions for its lead product, ZELSUVMI, increased following the treatment's July 2025 commercial launch. The company also discussed an accounting restatement related to the fair-value measurement of convertible debt and outlined expected 2027 launches for its complementary products XEPI and XEGLYZE.
Pelthos Therapeutics Inc. (PTHS) Q2 2026 Earnings Call Transcript
Pelthos Therapeutics Inc. (PTHS) came out with a quarterly loss of $6.62 per share versus the Zacks Consensus Estimate of a loss of $3.02. This compares to a loss of $5.38 per share a year ago.
Zelsuvmi ® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026